The Vanguard Group 13D and 13G filings for Y-mAbs Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 6:00 pm Unchanged | 2024-09-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB | The Vanguard Group | 2,035,363 4.560% | 0 (Unchanged) | Filing |
| 2024-11-04 2:16 pm Sale | 2024-09-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB | The Vanguard Group | 2,035,363 4.560% | -208,875 (-9.31%) | Filing |
| 2024-02-13 5:17 pm Sale | 2023-12-29 | 13G | Y-mAbs Therapeutics, Inc. YMAB | The Vanguard Group | 2,244,238 5.140% | -14,016 (-0.62%) | Filing |
| 2023-02-09 11:37 am Purchase | 2022-12-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB | The Vanguard Group | 2,258,254 5.170% | 2,258,254 (New Position) | Filing |